Revealed at an event earlier this month, the Ion is now home to installations by Houston-based artists Christopher Blay and Kill Joy, which play on the traditional window displays the building hosted for years as the historic Sears Building. Photo courtesy of Marc Furi Creative/the Ion

Two new art installations at the Ion speak to the building's past and its potential future.

Revealed at an event earlier this month, the innovation hub developed by Rice University is now home to installations by Houston-based artists Christopher Blay and Kill Joy, which play on the traditional window displays the building hosted for years as the historic Sears Building.

The pieces are part of the Ion's Eye on Art program, according to a release. Each was selected by the Ion and Ion District Art Advisory Council with support from Piper Faust.

"Innovation and art have a lot more in common than you might think. Many of our local artists learn how to use emerging technologies to create their pieces and hone their craft,” Jan E. Odegard, executive director of the Ion, says in a statement. “Creativity plays a vital role in fostering innovation and we’re honored to provide artists like Christopher and Kill Joy with a platform to serve as an inspiration for the entire innovation ecosystem here at the Ion.”

Blay, who's an artist, writer and currently serves as the chief curator of the Houston Museum of African American Culture, created his installation in collaboration with the Ion Prototyping Lab. Using canvases and wood frames, the installation depicts slaving vessels and spaceships to "symbolizes where the Black community has been and where they are going," according to the Ion.

The installation is part of Blay's latest body of work, “The SpLaVCe Program."

Joy's work focuses on environmental and social justice. Her installation at the Ion, “Creation, Current, Solution," uses animated puppets inspired by Filipino folklore to explore the intersection of technology and sustainable living.

Blay and Joy's installations will be on display for the next six months, and will rotate out to feature other Houston-based artists' work.

The Ion first launched the The Eye On Art Program in March 2022. The debut displays included Lina Dib’s over-the-top kitsch “Self-Portrait in the Garden” and Preston Gaines' multi-sensory “Fantasy Landscape.” The second rotation featured Lisa Morales and Stacey Gresell’s “The Collective Hive” and “Exploración Orgánica” by Maria Rodriguez, Miriam Mireles, Bryce Saucier, Timothy Hudson, and Victoria Armenta: “Exploración Orgánica”

Earlier this summer, the Ion also announced that it would launch its official workforce development partner’s 12- to 15- week technology skills training courses this fall.

Click through photos from the new installation below.

“The SpLaVCe Program" by Christopher Blay

Photo courtesy of Marc Furi Creative/the Ion

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”